project id: TCGA-BLCA; case submitter id: TCGA-FD-A3N5; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.8; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.4; rna integrity number: 7.7; age at index: 69; days to birth: -25342; days to death: 685; ethnicity: not hispanic or latino; gender: male; race: black or african american; vital status: Dead; year of birth: 1942; age at diagnosis: 25342; ajcc pathologic m: MX; ajcc pathologic n: N0; ajcc pathologic stage: Stage II; ajcc pathologic t: T2b; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 363.0; icd 10 code: C67.4; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Posterior wall of bladder; synchronous malignancy: No; tissue or organ of origin: Posterior wall of bladder; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: no; alcohol history: Not Reported; cigarettes per day: 2.191780821917808; pack years smoked: 40.0; is ffpe: false; composition: Not Reported; days to collection: 260; days to sample procurement: 0; initial weight: 330.0; portion submitter id: TCGA-FD-A3N5-01A-11; percent lymphocyte infiltration: 2.0; percent monocyte infiltration: 1.0; percent necrosis: 7.0; percent neutrophil infiltration: 1.0; percent normal cells: 0.0; percent stromal cells: 13.0; percent tumor cells: 80.0; percent tumor nuclei: 80.0;